Novel non-covalent conjugate based on graphene oxide and alkylating agent from 1,3,5-triazine class

One of the ways to increase the specificity and biocompatibility of cytostatic drugs is the creation of conjugates of drugs with graphene oxide. Graphene and its oxidized form - graphene oxide (GO) - have become new promising materials in the field of nanomedicine due to its reactive and developed surface that can be subjected to covalent and non-covalent functionalization, which allows provide the immobilization of drugs. This article is devoted to a new method for the synthesis, identification and study of the biocompatibility of a non-covalent conjugate based on GO and an alkylating agent based on 1,3,5triazine. The conjugates are hemocompatible (the degree of hemolysis does not exceed 5 % in the concentration range 1-200 mg center dot l-1), exhibit antioxidant activity in the model reaction with DPPH, Radachlorin (the photodegradation constant decreased by 1.7 times at the maximum concentration of GO-1 75 mg center dot l-1) and photoinduced hemolysis, has dose-dependent genotoxicity, and also exhibit cytotoxicity towards cell lines A549, PANC-1 and HeLa. The maximum cytotoxicity is shown in the HeLa cell line (IC50 = 2.5 lM). (c) 2023 Published by Elsevier B.V.

Automated summary

This article explores a method of increasing the specificity and biocompatibility of cytostatic drugs by creating conjugates with graphene oxide. Graphene oxide is a new and promising material in the field of nanomedicine due to its reactive and developed surface, which allows for functionalization and immobilization of drugs. The study focuses on a non-covalent conjugate of graphene oxide and a alkylating agent, and evaluates its biocompatibility through various tests. The results show that the conjugate is hemocompatible, exhibits antioxidant activity, induces photoinduced hemolysis, and demonstrates dose-dependent genotoxicity and cytotoxicity towards specific cell lines.